A Comparison of Fidaxomicin and Vancomycin in Patients With CDI Receiving Antibiotics for Concurrent Infections

Exclusion Criteria

• •Patients with severe-complicated disease that would compromise oral therapy (hypotenstion or shock, ileus or bowel obstruction, megacolon).
• •Patients with an allergy to oral vancomycin or fidaxomicin.
• •Patients anticipated to receive metronidazole after enrollment.
• •Patients who already received oral vancomycin or metronidazole (either oral or intravenous) for \> 24 hours within the preceding 72 hours at the time of enrollment.
• •Patients anticipated to receive adjunctive C. difficile therapy (rifaxamin, nitazoxanide, tigecycline) after enrollment.
• •Patients who are on laxatives before they are enrolled into the study, such as lactulose, if:
• •* Patients have had a recent dose adjustment;
• •* Baseline number of bowel movement while on laxatives is unknown.
• •* Number of bowel movements and/or consistency has not changed from baseline.
• •Patients who have had colostomy or ileostomy
• •Patients who will have colostomy or ileostomy after enrollment and before study ends
• •Patients who are or will be on long-term (\>12 weeks) medium or high-risk antibiotics prophylaxis after enrollment